Although TDT is developing diagnostics and therapeutics for several gastrointestinal cancers and diseases, our immediate-term focus is colorectal cancer. The blood test for recurrent colorectal cancer was launched in January 2003. Please check our website periodically for the availability out GC-C lymph node test.

• GC-C Lymph Node Test - to accurately stage patients for optimum post-surgical management
• GC-C Blood Test - to monitor for recurrent disease

These tests represent an improvement in sensitivity and specificity over the current standard methods, which can fail to detect colorectal cancer 30%-60% of the time.

Topics in this section include:

• TDT's breakthrough technology and its implications for assessing and monitoring colon cancer for recurrence
• TDT's Staging Test
• TDT's Post-Operative Monitoring Test
• Colon Cancer Test Comparisons